Baker BROS. Advisors LP Takes $4.86 Million Position in MBX Biosciences, Inc. $MBX

Baker BROS. Advisors LP purchased a new stake in MBX Biosciences, Inc. (NASDAQ:MBX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 277,777 shares of the company’s stock, valued at approximately $4,861,000. Baker BROS. Advisors LP owned approximately 0.62% of MBX Biosciences at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Creative Planning purchased a new position in MBX Biosciences in the third quarter worth $503,000. SummitTX Capital L.P. purchased a new stake in shares of MBX Biosciences during the 3rd quarter worth $513,000. Deep Track Capital LP grew its stake in shares of MBX Biosciences by 43.9% during the 3rd quarter. Deep Track Capital LP now owns 3,150,000 shares of the company’s stock worth $55,125,000 after purchasing an additional 961,408 shares during the period. Burkehill Global Management LP acquired a new position in shares of MBX Biosciences during the 3rd quarter worth $1,750,000. Finally, Man Group plc purchased a new position in shares of MBX Biosciences in the 3rd quarter valued at about $179,000.

MBX Biosciences Stock Up 0.2%

MBX Biosciences stock opened at $28.00 on Friday. The firm has a market capitalization of $1.26 billion, a PE ratio of -11.62 and a beta of 1.06. MBX Biosciences, Inc. has a 52 week low of $4.81 and a 52 week high of $44.89. The firm’s 50-day simple moving average is $35.57 and its 200 day simple moving average is $26.61.

MBX Biosciences (NASDAQ:MBX) last posted its earnings results on Thursday, March 12th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.15.

Analyst Ratings Changes

MBX has been the subject of several recent analyst reports. Stifel Nicolaus raised their price objective on shares of MBX Biosciences from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, December 19th. UBS Group restated a “buy” rating on shares of MBX Biosciences in a research report on Tuesday, February 24th. Wall Street Zen upgraded shares of MBX Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, December 21st. The Goldman Sachs Group assumed coverage on MBX Biosciences in a research note on Thursday, December 4th. They set a “sell” rating and a $18.00 price target on the stock. Finally, Truist Financial set a $50.00 price target on MBX Biosciences in a report on Monday, March 9th. Ten analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $51.56.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.